401 related articles for article (PubMed ID: 29560813)
21. Ataxin-2 gene: a powerful modulator of neurological disorders.
Laffita-Mesa JM; Paucar M; Svenningsson P
Curr Opin Neurol; 2021 Aug; 34(4):578-588. PubMed ID: 34010218
[TBL] [Abstract][Full Text] [Related]
22. Both ubiquitin ligases FBXW8 and PARK2 are sequestrated into insolubility by ATXN2 PolyQ expansions, but only FBXW8 expression is dysregulated.
Halbach MV; Stehning T; Damrath E; Jendrach M; Şen NE; Başak AN; Auburger G
PLoS One; 2015; 10(3):e0121089. PubMed ID: 25790475
[TBL] [Abstract][Full Text] [Related]
23. Cerebellar neuronal loss in amyotrophic lateral sclerosis cases with ATXN2 intermediate repeat expansions.
Tan RH; Kril JJ; McGinley C; Hassani M; Masuda-Suzukake M; Hasegawa M; Mito R; Kiernan MC; Halliday GM
Ann Neurol; 2016 Feb; 79(2):295-305. PubMed ID: 26599997
[TBL] [Abstract][Full Text] [Related]
24. Genetic ablation of ataxin-2 increases several global translation factors in their transcript abundance but decreases translation rate.
Fittschen M; Lastres-Becker I; Halbach MV; Damrath E; Gispert S; Azizov M; Walter M; Müller S; Auburger G
Neurogenetics; 2015 Jul; 16(3):181-92. PubMed ID: 25721894
[TBL] [Abstract][Full Text] [Related]
25. Atxn2 Knockout and CAG42-Knock-in Cerebellum Shows Similarly Dysregulated Expression in Calcium Homeostasis Pathway.
Halbach MV; Gispert S; Stehning T; Damrath E; Walter M; Auburger G
Cerebellum; 2017 Feb; 16(1):68-81. PubMed ID: 26868665
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic Antisense Targeting of Huntingtin.
Smith AV; Tabrizi SJ
DNA Cell Biol; 2020 Feb; 39(2):154-158. PubMed ID: 31821021
[TBL] [Abstract][Full Text] [Related]
27. Molecular Mechanisms and Therapeutics for Spinocerebellar Ataxia Type 2.
Egorova PA; Bezprozvanny IB
Neurotherapeutics; 2019 Oct; 16(4):1050-1073. PubMed ID: 31435879
[TBL] [Abstract][Full Text] [Related]
28. Antisense oligonucleotides: A primer.
Scoles DR; Minikel EV; Pulst SM
Neurol Genet; 2019 Apr; 5(2):e323. PubMed ID: 31119194
[TBL] [Abstract][Full Text] [Related]
29. ASO Therapy: Hope for Genetic Neurological Diseases.
Muth CC
JAMA; 2018 Feb; 319(7):644-646. PubMed ID: 29383373
[No Abstract] [Full Text] [Related]
30. Cerebellar Micro-RNA Profile in a Mouse Model of Spinocerebellar Ataxia Type 2.
Paul S; Dansithong W; Gandelman M; Figueroa KP; Scoles DR; Pulst SM
Neurol Genet; 2024 Apr; 10(2):e200144. PubMed ID: 38715656
[TBL] [Abstract][Full Text] [Related]
31. NCALD Antisense Oligonucleotide Therapy in Addition to Nusinersen further Ameliorates Spinal Muscular Atrophy in Mice.
Torres-Benito L; Schneider S; Rombo R; Ling KK; Grysko V; Upadhyay A; Kononenko NL; Rigo F; Bennett CF; Wirth B
Am J Hum Genet; 2019 Jul; 105(1):221-230. PubMed ID: 31230718
[TBL] [Abstract][Full Text] [Related]
32. Translating Antisense Technology into a Treatment for Huntington's Disease.
Lane RM; Smith A; Baumann T; Gleichmann M; Norris D; Bennett CF; Kordasiewicz H
Methods Mol Biol; 2018; 1780():497-523. PubMed ID: 29856033
[TBL] [Abstract][Full Text] [Related]
33. Antisense oligonucleotides targeting mutant Ataxin-7 restore visual function in a mouse model of spinocerebellar ataxia type 7.
Niu C; Prakash TP; Kim A; Quach JL; Huryn LA; Yang Y; Lopez E; Jazayeri A; Hung G; Sopher BL; Brooks BP; Swayze EE; Bennett CF; La Spada AR
Sci Transl Med; 2018 Oct; 10(465):. PubMed ID: 30381411
[TBL] [Abstract][Full Text] [Related]
34. Atxn2-CAG100-KnockIn mouse spinal cord shows progressive TDP43 pathology associated with cholesterol biosynthesis suppression.
Canet-Pons J; Sen NE; Arsović A; Almaguer-Mederos LE; Halbach MV; Key J; Döring C; Kerksiek A; Picchiarelli G; Cassel R; René F; Dieterlé S; Fuchs NV; König R; Dupuis L; Lütjohann D; Gispert S; Auburger G
Neurobiol Dis; 2021 May; 152():105289. PubMed ID: 33577922
[TBL] [Abstract][Full Text] [Related]
35. Mouse Ataxin-2 Expansion Downregulates CamKII and Other Calcium Signaling Factors, Impairing Granule-Purkinje Neuron Synaptic Strength.
Arsović A; Halbach MV; Canet-Pons J; Esen-Sehir D; Döring C; Freudenberg F; Czechowska N; Seidel K; Baader SL; Gispert S; Sen NE; Auburger G
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32932600
[TBL] [Abstract][Full Text] [Related]
36. The polyglutamine protein ATXN2: from its molecular functions to its involvement in disease.
Costa RG; Conceição A; Matos CA; Nóbrega C
Cell Death Dis; 2024 Jun; 15(6):415. PubMed ID: 38877004
[TBL] [Abstract][Full Text] [Related]
37. Antisense oligonucleotides in therapy for neurodegenerative disorders.
Evers MM; Toonen LJ; van Roon-Mom WM
Adv Drug Deliv Rev; 2015 Jun; 87():90-103. PubMed ID: 25797014
[TBL] [Abstract][Full Text] [Related]
38. Efficient Prevention of Neurodegenerative Diseases by Depletion of Starvation Response Factor Ataxin-2.
Auburger G; Sen NE; Meierhofer D; Başak AN; Gitler AD
Trends Neurosci; 2017 Aug; 40(8):507-516. PubMed ID: 28684172
[TBL] [Abstract][Full Text] [Related]
39. Antisense oligonucleotides in neurological disorders.
Wurster CD; Ludolph AC
Ther Adv Neurol Disord; 2018; 11():1756286418776932. PubMed ID: 29854003
[TBL] [Abstract][Full Text] [Related]
40. Antisense therapies for movement disorders.
Scoles DR; Pulst SM
Mov Disord; 2019 Aug; 34(8):1112-1119. PubMed ID: 31283857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
